140
Participants
Start Date
March 14, 2024
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
H107e
Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29
CAF®10b
Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29
H107e/CAF®10b - low adjuvant dose
Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29
H107e/CAF®10b - full adjuvant dose
Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
Low dose intranasal H107e
Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85
Full dose intranasal H107e
Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85
H107e/CAF®10b
Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
i.m. placebo
Participants will receive two i.m. injections of placebo on Day 1 and Day 29
BCG
Participants will receive one i.d. injection of BCG on Day 1
i.d. placebo
Participants will receive one i.d. injection of placebo on Day 1
Intranasal H107e
Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
RECRUITING
Aurum Institute, Pretoria
Collaborators (1)
Aurum Institute
OTHER
Bill and Melinda Gates Foundation
OTHER
Leiden University Medical Center
OTHER
South African Tuberculosis Vaccine Initiative
OTHER
Statens Serum Institut
OTHER